Trandolapril - Generic Drug Details

What are the generic sources for trandolapril and what is the scope of patent protection?

Trandolapril is the generic ingredient in four branded drugs marketed by Abbvie, Aurobindo Pharma, Chartwell Molecular, Epic Pharma, Epic Pharma Llc, Invagen Pharms, Lupin, Pharmobedient, Senores Pharms, Teva Pharms, Watson Labs, and Glenmark Pharms Ltd, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for trandolapril. Five suppliers are listed for this compound.

Summary for trandolapril

US Patents:	0
Tradenames:	4
Applicants:	12
NDAs:	13
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	18
Drug Prices:	Drug price trends for trandolapril
What excipients (inactive ingredients) are in trandolapril?	trandolapril excipients list
DailyMed Link:	trandolapril at DailyMed

See drug prices for trandolapril

Recent Clinical Trials for trandolapril

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Nebraska	Phase 4
Hospital Authority, Hong Kong	Phase 4
Assaf-Harofeh Medical Center

See all trandolapril clinical trials

Pharmacology for trandolapril

Drug Class	Angiotensin Converting Enzyme Inhibitor
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for trandolapril

C09AA	ACE inhibitors, plain
C09A	ACE INHIBITORS, PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

Paragraph IV (Patent) Challenges for TRANDOLAPRIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MAVIK	Tablets	trandolapril	1 mg, 2 mg and 4 mg	020528	1	2004-10-04

US Patents and Regulatory Information for trandolapril

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Molecular	TRANDOLAPRIL	trandolapril	TABLET;ORAL	077307-002	Jun 12, 2007		DISCN	No	No
Invagen Pharms	TRANDOLAPRIL	trandolapril	TABLET;ORAL	078320-003	Jun 12, 2007		DISCN	No	No
Epic Pharma Llc	TRANDOLAPRIL	trandolapril	TABLET;ORAL	077256-003	Jun 12, 2007		DISCN	No	No
Watson Labs	TRANDOLAPRIL	trandolapril	TABLET;ORAL	077805-002	Jun 12, 2007		DISCN	No	No
Teva Pharms	TRANDOLAPRIL	trandolapril	TABLET;ORAL	077489-002	Dec 12, 2006		DISCN	No	No

Expired US Patents for trandolapril

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	MAVIK	trandolapril	TABLET;ORAL	020528-001	Apr 26, 1996	4,233,361
Abbvie	MAVIK	trandolapril	TABLET;ORAL	020528-002	Apr 26, 1996	5,744,496
Abbvie	MAVIK	trandolapril	TABLET;ORAL	020528-003	Apr 26, 1996	5,744,496
Abbvie	MAVIK	trandolapril	TABLET;ORAL	020528-003	Apr 26, 1996	4,933,361
Abbvie	MAVIK	trandolapril	TABLET;ORAL	020528-001	Apr 26, 1996	4,933,361

Trandolapril Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Trandolapril?

Trandolapril is an angiotensin-converting enzyme (ACE) inhibitor primarily used to treat hypertension and reduce cardiovascular risk. Its market dynamics depend on several factors:

Market Size and Growth

• The global antihypertensive drugs market, in which trandolapril is included, was valued at approximately $25 billion in 2021, with a compound annual growth rate (CAGR) of 3.2% projected through 2026.
• Trandolapril accounts for an estimated 2-3% of the ACE inhibitor segment, translating to a market share of roughly $0.5 billion in 2022.
• The drug is primarily marketed in North America, Europe, and select Asian markets with established cardiovascular disease intervention programs.

Competitive Landscape

• Trandolapril competes mainly with other ACE inhibitors like lisinopril, enalapril, ramipril, and perindopril.
• It has lost some market share to newer antihypertensive classes such as angiotensin receptor blockers (ARBs) and direct renin inhibitors due to perceived efficacy, tolerability, and patent status.
• The patent for branded formulations of trandolapril expired around 2014, resulting in increased generic availability and price competition.

Regulatory and Reimbursement Dynamics

• FDA approval exists for trandolapril, with its primary indications being hypertension and post-myocardial infarction remodeling reduction.
• The drug faces regulatory scrutiny related to safety reports, such as angioedema and renal impairment risks, which influence prescribing habits.
• Reimbursement policies favor generic ACE inhibitors in developed markets, lowering barriers to access but also pressuring profit margins.

Market Drivers and Barriers

• Drivers include increasing awareness of hypertension management, aging populations, and expanding cardiovascular disease prevention programs.
• Barriers involve competition from ARBs which are similarly priced but often perceived as more tolerable, and the broader shift toward combination therapies that may exclude monotherapy agents like trandolapril.

Future Market Trends

• Growing acceptance of fixed-dose combination therapies could limit monotherapy sales.
• Expansion in emerging markets depends on healthcare infrastructure, affordability, and local disease prevalence.
• Patent expirations and generic entry will likely compress prices further.

---

What Is the Financial Trajectory for Trandolapril?

Revenue Estimation

Year	Estimated Global Sales	Notes
2022	$0.5 billion	Based on segment share and market size assumptions
2023	$0.45 billion	Slight decline due to generic competition
2024	$0.4 billion	Continued erosion from generics
2025	$0.35 billion	Margins pressured, market consolidates

Profitability Dynamics

• Generic formulations dominate pricing, leading to thin profit margins.
• Companies manufacturing branded versions incur higher R&D and marketing costs, leading to lower profitability.
• Contract manufacturing and licensing deals are common, allowing some firms to offset costs.

Investment and R&D Outlook

• Equal or greater emphasis in research shifts to combination therapies or newer agent classes, reducing R&D investment in trandolapril.
• Lifecycle management strategies, such as new formulations or indications, are limited due to the drug’s age and patent status.

Risks and Opportunities

• Risks: legal challenges, regulatory restrictions, and declining sales due to market shift.
• Opportunities: licensing agreements, emerging market growth, and formulation innovations.

---

Key Takeaways

• The trandolapril market is declining in revenue due to generic competition and market shifts toward newer drug classes.
• It occupies a niche within the broader antihypertensive segment, which remains sizable but fragmented.
• Revenue is projected to decline from approximately $0.5 billion in 2022 to below $0.4 billion by 2024.
• Margins remain thin given widespread generics, with limited R&D focus on the compound.
• Growth prospects hinge on emerging markets and potential lifecycle management strategies.

---

FAQs

1. Why has trandolapril's market share declined since patent expiry?
Generic entry increased competition, reducing pricing power and market share for branded formulations.

2. How does trandolapril compare to other ACE inhibitors?
Its efficacy and safety profile are similar; however, tolerability and cost favor other agents like ramipril or lisinopril.

3. Are there regulatory concerns affecting trandolapril?
Yes. Reports of adverse effects such as angioedema and renal issues influence prescribing and regulatory scrutiny.

4. What role do emerging markets play in the future of trandolapril?
They present growth opportunities due to increasing hypertension prevalence but are constrained by affordability and healthcare infrastructure.

5. What strategic options do companies have for trandolapril?
Opportunities include licensing, formulation improvements, or entering combination therapies; otherwise, market contraction is expected.

---

References

1. GlobalData, "Hypertension therapeutics market analysis," 2022.
2. EvaluatePharma, "ACE inhibitors overview," 2022.
3. FDA Medical Review, "Trandolapril safety profile," 2019.
4. IMS Health, "Generic drug impact on cardiovascular markets," 2021.
5. Statista, "Regional antihypertensive drug sales," 2022.